Treating C3 glomerulopathy with eculizumab
BMC Nephrology, 2018 Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well as inherited dysregulation of the alternative pathway of the complement cascade ...
Thomas Welte +7 more
doaj +2 more sources
Eculizumab as Additional Rescue Therapy in Myasthenic Crisis
MusclesEculizumab is a monoclonal antibody blocking the terminal complement protein C5. As demonstrated in the phase III randomized, placebo-controlled, REGAIN clinical trial, eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive ...
Francesco Crescenzo +8 more
doaj +2 more sources
Complement inhibitor therapy in atypical hemolytic uremic syndrome (aHUS): evaluating the economic impact of introducing eculizumab biosimilars in Germany [PDF]
BMC NephrologyBackground Eculizumab, a humanized monoclonal antibody, inhibits activation of complement component C5. For patients with atypical hemolytic uremic syndrome, the introduction of eculizumab has markedly improved survival, restoring life expectancy close ...
Isabell Kaufhold +4 more
doaj +2 more sources
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome [PDF]
Clinical Pharmacology: Advances and Applications, 2011 Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed ...
Ohanian M, Cable CC, Halka KK
doaj +2 more sources
Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. [PDF]
Eur J NeurolABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Meisel A +17 more
europepmc +2 more sources
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, 2022 One of the treatment options for complement-mediated thrombotic microangiopathy (CM-TMA), also known as atypical hemolytic uremic syndrome, is the administration of the C5 complement inhibitor eculizumab.
Meera Sridharan, MD, PhD +2 more
doaj +1 more source
Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
Frontiers in Pediatrics, 2021 Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Saritha Ranabothu +5 more
doaj +1 more source
Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis
Frontiers in Neurology, 2021 Objective: To investigate the pharmacokinetics, pharmacodynamics, and exposure–response of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with generalized myasthenia gravis (gMG ...
Jonathan P. R. Monteleone +4 more
doaj +1 more source
Children, 2022 Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab.
Saeed AlZabali +18 more
doaj +1 more source
Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report
Case Reports in Neurology, 2021 The recombinant humanized monoclonal antibody eculizumab has been shown to be effective and well tolerated in patients with anti-acetylcholine receptor antibody-positive, treatment-refractory generalized myasthenia gravis (gMG).
Tuan Vu +4 more
doaj +1 more source